The Oncotype DX Genomic Prostate Score (GPS) assay uses genomics to help predict the aggressiveness of prostate tumors. A genomic test measures expression or sequence of genes within a sample of tumor tissue.
Oncotype DX GPS is the only genomic test that was designed specifically for use in men with clinically low risk cancer (GS 3+3 and 3+4) who are deciding between active surveillance and treatment. This genomic test:
The only genomic assay designed to help make treatment decisions at the time of diagnosis
- Has been validated in multiple contemporary and clinically-relevant patient populations.1-3
- Requires a very small sample of tumor from a single-needle biopsy core.1,2
- Assess expression of genes that are reliably recovered and predictive of clinically relevant outcomes across multiple tumor foci.1,2
- Provides information that is distinct from other clinical parameters like prostate-specific antigen (PSA) level and Gleason score.1-3
- Refines risk based on estimation of likelihood of aggressive disease.1-3
- Is included in National Comprehensive Cancer Network® (NCCN) guidelines as an option to help guide management decisions.7
Genomic testing vs. genetic testing
Genetic tests typically screen for inherited risk factors and identify changes in chromosomes and genes—which can help in understanding patient risk for having cancer or other diseases.
Genomic tests examines the activity and sequence of genes within a sample of tumor tissue to provide unique information about tumor biology that other clinical pathological factors simply cannot. The activity and interaction of genes influences the behavior of a tumor, including its aggressiveness and how likely it is to grow and spread.
Confidently recommend a course of care
Although biopsies provide important information, they sample very small areas of the prostate and don’t always convey an accurate assessment of the aggressiveness and the extent of the cancer. The Oncotype DX GPS assay is designed to provide precise and predictive information you need to more confidently assess risk and guide treatment decisions for your clinically low-risk prostate cancer patients.
The Oncotype DX GPS provides insight into how aggressive a tumor might be, which is essential in management planning, when you consider:
- Prostate cancer accounts for 11% of all cancers and over 26,000 cancer related deaths every year.8
- There is a ~1% chance that low-risk prostate cancer will progress to become life threatening within 10 years of diagnosis.9
- Not all prostate cancers need immediate treatment—studies show that many men with low-risk disease can be successfully and safely managed with active surveillance.10,11
The Oncotype DX GPS is available from Genomic Health, the world’s leading molecular diagnostics company which has a rigorous process for developing and validating genomic-based tests.